These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 19958824)
41. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Hecq J; Deleers M; Fanara D; Vranckx H; Boulanger P; Le Lamer S; Amighi K Eur J Pharm Biopharm; 2006 Nov; 64(3):360-8. PubMed ID: 16846725 [TBL] [Abstract][Full Text] [Related]
42. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization. Yu JM; Li YJ; Qiu LY; Jin Y J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361 [TBL] [Abstract][Full Text] [Related]
43. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Sarmento B; Ribeiro A; Veiga F; Ferreira D; Neufeld R Biomacromolecules; 2007 Oct; 8(10):3054-60. PubMed ID: 17877397 [TBL] [Abstract][Full Text] [Related]
44. Characterization of chitosan thiolation and application to thiol quantification onto nanoparticle surface. Bravo-Osuna I; Teutonico D; Arpicco S; Vauthier C; Ponchel G Int J Pharm; 2007 Aug; 340(1-2):173-81. PubMed ID: 17592748 [TBL] [Abstract][Full Text] [Related]
45. Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. Nafee N; Schneider M; Schaefer UF; Lehr CM Int J Pharm; 2009 Nov; 381(2):130-9. PubMed ID: 19450671 [TBL] [Abstract][Full Text] [Related]
46. Alginate microspheres of isoniazid for oral sustained drug delivery. Rastogi R; Sultana Y; Aqil M; Ali A; Kumar S; Chuttani K; Mishra AK Int J Pharm; 2007 Apr; 334(1-2):71-7. PubMed ID: 17113732 [TBL] [Abstract][Full Text] [Related]
47. Tuning of shell and core characteristics of chitosan-decorated acrylic nanoparticles. Bravo-Osuna I; Ponchel G; Vauthier C Eur J Pharm Sci; 2007 Feb; 30(2):143-54. PubMed ID: 17157487 [TBL] [Abstract][Full Text] [Related]
48. Mathematical modelling of the transport of hydroxypropyl-β-cyclodextrin inclusion complexes of ranitidine hydrochloride and furosemide loaded chitosan nanoparticles across a Caco-2 cell monolayer. Sadighi A; Ostad SN; Rezayat SM; Foroutan M; Faramarzi MA; Dorkoosh FA Int J Pharm; 2012 Jan; 422(1-2):479-88. PubMed ID: 22101294 [TBL] [Abstract][Full Text] [Related]
49. Preparation and improvement of release behavior of chitosan microspheres containing insulin. Wang LY; Gu YH; Su ZG; Ma GH Int J Pharm; 2006 Mar; 311(1-2):187-95. PubMed ID: 16436319 [TBL] [Abstract][Full Text] [Related]
50. A novel, biodegradable and reversible polyelectrolyte platform for topical-colonic delivery of pentosan polysulphate. Shah HK; Conkie JA; Tait RC; Johnson JR; Wilson CG Int J Pharm; 2011 Feb; 404(1-2):124-32. PubMed ID: 21093555 [TBL] [Abstract][Full Text] [Related]
51. Enhanced intestinal permeability and oral bioavailability of enalapril maleate upon complexation with the cationic polymethacrylate Eudragit E100. Ramírez-Rigo MV; Olivera ME; Rubio M; Manzo RH Eur J Pharm Sci; 2014 May; 55():1-11. PubMed ID: 24456933 [TBL] [Abstract][Full Text] [Related]
52. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Chen MC; Wong HS; Lin KJ; Chen HL; Wey SP; Sonaje K; Lin YH; Chu CY; Sung HW Biomaterials; 2009 Dec; 30(34):6629-37. PubMed ID: 19767097 [TBL] [Abstract][Full Text] [Related]
53. Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. Krauland AH; Alonso MJ Int J Pharm; 2007 Aug; 340(1-2):134-42. PubMed ID: 17459620 [TBL] [Abstract][Full Text] [Related]
54. Alkanoylsucroses in nasal delivery of low molecular weight heparins: in-vivo absorption and reversibility studies in rats. Yang T; Mustafa F; Ahsan F J Pharm Pharmacol; 2004 Jan; 56(1):53-60. PubMed ID: 14980001 [TBL] [Abstract][Full Text] [Related]
55. Nasal absorption and local tissue reaction of insulin nanocomplexes of trimethyl chitosan derivatives in rats. Jintapattanakit A; Peungvicha P; Sailasuta A; Kissel T; Junyaprasert VB J Pharm Pharmacol; 2010 May; 62(5):583-91. PubMed ID: 20609059 [TBL] [Abstract][Full Text] [Related]
56. Preparation and evaluation of alpha-phenyl-n-tert-butyl nitrone (PBN)-encapsulated chitosan and PEGylated chitosan nanoparticles. Pinarbasli O; Aktas Y; Dalkara T; Andrieux K; Alonso MJ; Fernandez-Megia E; Novoa-Carballal R; Riguera R; Couvreur P; Capan Y Pharmazie; 2009 Jul; 64(7):436-9. PubMed ID: 19694179 [TBL] [Abstract][Full Text] [Related]
57. Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system. Han HK; Shin HJ; Ha DH Eur J Pharm Sci; 2012 Aug; 46(5):500-7. PubMed ID: 22522117 [TBL] [Abstract][Full Text] [Related]
58. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Wang X; Chi N; Tang X Eur J Pharm Biopharm; 2008 Nov; 70(3):735-40. PubMed ID: 18684400 [TBL] [Abstract][Full Text] [Related]
59. Elaboration of chitosan-coated nanoparticles loaded with curcumin for mucoadhesive applications. Mazzarino L; Travelet C; Ortega-Murillo S; Otsuka I; Pignot-Paintrand I; Lemos-Senna E; Borsali R J Colloid Interface Sci; 2012 Mar; 370(1):58-66. PubMed ID: 22284577 [TBL] [Abstract][Full Text] [Related]